Thursday, June 30, 2022

561.316.3330

Dr Paul Brooks Appointed Chief Business Officer of CN Bio

Latest Posts

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

The technology licensed from Synaffix include GlycoConnect™, HydraSpace™, and multiple toxSYN™ linker-payloads, which allow for the drug-to-antibody ratio (DAR) to be tailored to 1, 2 or 4 to optimize the therapeutic index of the ADC.

Ingenza Awarded Government Funding

Ingenza advises the project aims to develop a novel CO2 conversion technology, which will capture industrial CO2 emissions and convert them into formate, a versatile chemical that can be used across various industries, including pharmaceuticals and agriculture.

MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines & Diagnostics for Chronic Metabolic Disease

MultiOmic Health advises the partnership will provide access to data from patient populations in Asia that have historically been underrepresented in chronic metabolic disease studies.

BD Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

BD notes the test uses a single nasal swab or a single nasopharyngeal swab sample to determine if a patient has COVID-19 or the flu or RSV. It helps eliminate the need for multiple tests or doctor visits and can help clinicians to implement the right treatment plan quickly.

Dr Paul Brooks will be responsible for shaping the company’s commercial business strategy and leading the expansion of its global commercial organization.

Dr Paul Brooks is an experienced C-suite level executive with over 25 years in the life science industry building businesses and leading high-performance research, product development, marketing, and sales teams to develop and commercialize new biotechnology technologies. He joins CN Bio from Horizon Discovery, a PerkinElmer Company, where he led the strategic and operational transformation of its business units as Head of Business Operations & Managing Director, driving revenue growth across its service, product, and licensing businesses. P

He held various management roles at Sigma-Aldrich; acquired by Merck Group in 2015 to form MilliporeSigma, where he joined the leadership team as Head of Discovery Research Services & General Manager and led the successful formation of its global-leading product and service portfolio for drug discovery research. In 2016, Dr Paul Brooks relocated back to the UK as Chief Commercial Officer & Executive Director and Board member at Oxford Genetics, driving the rapid scaling of the synthetic biology start-up company and commercialization of its technology.

Paul has a BSc in Biochemistry from the University of Wales, a Ph.D. in Molecular Biology from the University of Manchester Institute of Science and Technology, and an MBA from the University of Nottingham Business School.

Dr. David Hughes, Chief Executive Officer, CN Bio, said: “Paul not only has experience across a range of large, globally-recognized life sciences businesses but also driving growth within smaller teams. He has a very strong track record and is well placed to help us grow commercially, moving us forward with our organizational strategy and goals. We are proud to have him joining the team and look forward to working together, enabling us to drive innovation in the sector by bringing more products to market.”

Dr. Paul Brooks, Chief Business Officer, CN Bio, commented: “The potential within the Organ-on-a-Chip space to revolutionize drug discovery is remarkable. CN Bio is demonstrating these possibilities with its next-generation PhysioMimix micro physiological technology, not only to accelerate the accurate and reliable development of new therapeutics but also critically reducing researchers’ dependence on animal models. It’s an exciting time to be joining CN Bio at an important inflection point in its history, and I’m eager to work alongside the team to help realize this potential.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine